Data gathered: April 15
AI Stock Analysis - FibroGen (FGEN)
Analysis generated December 22, 2024. Powered by Chat GPT.
FibroGen, Inc. is a globally recognized biopharmaceutical company focused on developing and marketing innovative drugs to treat chronic and life-threatening conditions. Their pipeline primarily includes treatments for anemia, idiopathic pulmonary fibrosis, and pancreatic cancer. The robust nature of their project portfolio, coupled with strategic partnerships and clinical advancements, has placed them as a notable player in the healthcare sector.
Stock Alerts - FibroGen (FGEN)
 |
FibroGen | April 14 Price is up by 8.2% in the last 24h. |
|
FibroGen | April 11 Price is up by 7.3% in the last 24h. |
|
FibroGen | April 9 Price is down by -6.8% in the last 24h. |
|
FibroGen | April 8 Price is down by -6.4% in the last 24h. |
Alternative Data for FibroGen
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 13 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | 20 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 31 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,889 | Sign up | Sign up | Sign up |
| Twitter Followers | 989 | Sign up | Sign up | Sign up |
| Twitter Mentions | 12 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 41 | Sign up | Sign up | Sign up |
| Linkedin Employees | 320 | Sign up | Sign up | Sign up |
About FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
| Price | $0.30 |
| Target Price | Sign up |
| Volume | 764,710 |
| Market Cap | $28M |
| Year Range | $0.25 - $0.77 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
StockNews.com Initiates Coverage on FibroGen (NASDAQ:FGEN)April 7 - ETF Daily News |
 |
William Blair Forecasts FibroGen’s Q1 Earnings (NASDAQ:FGEN)April 4 - ETF Daily News |
|
FibroGen (FGEN) – Research Analysts’ Recent Ratings ChangesApril 2 - ETF Daily News |
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 2 - GlobeNewswire |
|
|
William Blair Reaffirms “Market Perform” Rating for FibroGen (NASDAQ:FGEN)April 1 - ETF Daily News |
|
FibroGen (NASDAQ:FGEN) Now Covered by StockNews.comMarch 30 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 46M | 5.3M | 41M | -17M | -12M | 0.015 |
| Q2 '24 | 51M | 5.2M | 45M | -16M | -11M | -0.160 |
| Q1 '24 | 51M | 26M | 25M | -33M | -28M | -0.330 |
| Q4 '23 | 38M | 5.4M | 32M | -56M | -51M | -0.570 |
| Q3 '23 | 35M | 4.2M | 31M | -64M | -59M | -0.520 |
Insider Transactions View All
| Wettig Thane filed to buy 543,329 shares at $0.3. March 25 '25 |
| Schoeneck James A filed to buy 373,722 shares at $0.3. March 24 '25 |
| Schoeneck James A filed to buy 323,722 shares at $0.4. March 24 '25 |
| Adib Deyaa filed to buy 82,123 shares at $1.2. June 13 '24 |
| Wettig Thane filed to buy 470,178 shares at $1.9. March 11 '24 |
Similar companies
Read more about FibroGen (FGEN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of FibroGen?
The Market Cap of FibroGen is $28M.
What is the current stock price of FibroGen?
Currently, the price of one share of FibroGen stock is $0.30.
How can I analyze the FGEN stock price chart for investment decisions?
The FGEN stock price chart above provides a comprehensive visual representation of FibroGen's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling FibroGen shares. Our platform offers an up-to-date FGEN stock price chart, along with technical data analysis and alternative data insights.
Does FGEN offer dividends to its shareholders?
As of our latest update, FibroGen (FGEN) does not offer dividends to its shareholders. Investors interested in FibroGen should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of FibroGen?
Some of the similar stocks of FibroGen are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.